Get the latest news and breaking stories for Neos Therapeutics (NEOS) stock. Stock analysis for Neos Therapeutics Inc (NEOS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. The CEO also probed into how the company is looking to continue its pattern of acquisition, consolidation, licensing and partnerships to add further value to Aytu's expanding presence in the biopharma field.Bringing It Back HomeDuring the course of the interview, Disbrow delved into his and his brother's history in biotech entrepreneurship, starting in 2006 when Jarrett Disbrow founded specialty pharmaceutical company Arbor Pharmaceuticals.Focusing primarily on the licensing and marketing of commercial-stage pediatric products, Jarrett was joined by his twin brother Josh in 2007 and the two built up the company and its products over the course of the next six years, from an initial capital pool of less than $500,000 to generating $250M in revenue by 2012. (NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. CEO Douglas M. VanOort said testing volumes appear to be … Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021. Find real-time NEOS - Neos Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX). DOW 0.00%. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. View all of NEOS's competitors. Real-time trade and investing ideas on Neos Therapeutics NEOS from the largest community of traders and investors. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. NASDAQ 0.00%. "Big markets in which we can compete and carve out a meaningful niche with novel brands. InvestorPlace 42d. Latest NEOS News From Around the Web. S&P 500 0.00%. Neo has also recently closed a deal with ZelCore wallet to increase mass adoption in the global economy. Neos Therapeutics Inc. loss -15.28% on the last trading session, reaching $0.69 price per share at the time. Neos Therapeutics Inc (NEOS) Stock Quote and News . The Chinese trading expert, Josh Rager points out that after this news surfaced all over, the trading volume of NEO increased by more than 1 billion USD. 0.856-0.042 (-4.68%) Upgrade to Real-Time Regular Market ... Neos stockholders will be entitled to receive 0.1088 shares of common stock of Aytu for each share of Neos common stock held, after taking into account the one-for-ten reverse split of Aytu’s common stock that was effected on December 8, 2020. Fundamental company data provided by Morningstar and Zacks Investment Research. The company earned $12.54 million during the quarter. View the latest Neos Therapeutics Inc. (NEOS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Find the latest NeoGenomics, Inc. (NEO) stock quote, history, news and other vital information to help you with your stock trading and investing. Want to see which stocks are moving? Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter. View Neos Therapeutics' earnings history. STOCKS. Neos Therapeutics (NEOS) stock price, charts, trades & the US's most popular discussion forums. View Neos Therapeutics, Inc. NEOS investment & stock information. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. NEOS Stock News. Wall Street analysts have given Neos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Only 3.80% of the stock of Neos Therapeutics is held by insiders. The official website for Neos Therapeutics is www.neostx.com. * neos therapeutics (neos… Ultimately, that strategy led to extremely rapid growth over the ensuing two-plus years. Receive a free world-class investing education from MarketBeat. Get the latest Neos Therapeutics, Inc. (NEOS) stock news and headlines to help you in your trading and investment decisions. All rights reserved. "I'm proud of how the transformation has taken hold. What's going on at Neos Therapeutics (NASDAQ:NEOS)? "Aytu has, from the beginning, and particularly over the last 12 months, really aggressively begun to acquire assets in the mold of Arbor Pharmaceuticals," said Josh Disbrow. Find the latest analyst research for Neos Therapeutics, Inc. Common Stock (NEOS) at Nasdaq.com. "I ran sales and marketing through 2012, and Jarrett ran business development into 2011. Neos Therapeutics news and NEOS price. "We already have infrastructure, know-how and capabilities within the pediatric and primary care realm, so the Neos products fit very well within that. NeoGenomics is already the leading oncology diagnostic testing provider in the U.S and has been further growing its market share. View today's stock price, news and analysis for Neos Therapeutics Inc. (NEOS). A recent spot check on the stock’s support and resistance revealed that the publicly-traded Neos Therapeutics Inc. (NASDAQ: NEOS) shares are trading at a price close to -28.56% lower than its 90-day high. Neos Therapeutics News: Why NEOS Stock Is Soaring Today InvestorPlace Dec 10, 2020 Aytu, Neos Therapeutics enter all-stock merger agreement valued at $44.9M Seeking Alpha Dec 10, 2020 "Disbrow cited the company's testosterone replacement drug, Natesto, as a key example. Disbrow had this to say about the news pushing NEOS stock higher today. All rights reserved. Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. View the real-time NEOS price chart on Robinhood and decide if you want to buy or sell commission-free. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Neos Therapeutics, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.Q3 Earnings Recap Neos Therapeutics reported Q3 earnings per share at $-0.1/share, which did not meet analyst predictions of $-0.05/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Thursday's Pre-Market Session * 12 Healthcare Stocks Moving In Tuesday's Intraday Session(C) 2020 Benzinga.com. Some companies that are related to Neos Therapeutics include DiaMedica Therapeutics (DMAC), Taiwan Liposome (TLC), FS Development (FSDC), vTv Therapeutics (VTVT), Enlivex Therapeutics (ENLV), Adamis Pharmaceuticals (ADMP), Ritter Pharmaceuticals (RTTR), Lumos Pharma (LUMO), Heat Biologics (HTBX), Spring Bank Pharmaceuticals (SBPH), Genprex (GNPX), Immunome (IMNM), Orgenesis (ORGS), Enochian Biosciences (ENOB) and Liminal BioSciences (LMNL). STOCKS. The P/E ratio of Neos Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference. Doug Parker has an approval rating of 60% among Neos Therapeutics' employees. Changes in earnings and sales indicate shifts in Neos Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. The capital turnover (annual revenue relative to shareholder's equity) for NEOS is -2.77 - … It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on NEOSReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. What this means: InvestorsObserver gives Neos Therapeutics (NEOS) an overall rank of 38, which is below average. Earnings for Neos Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.08) per share. Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Mine OK'd in Trump's last days may boost Biden energy plan, Insurers add food to coverage menu as way to improve health, DuPont, Chemours reach agreement over 'forever chemicals', Buy Kinder Morgan, Inc While It Still Yields 6.75%. Rooms Rankings Earnings Calendar Shop. MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. 1,448 employees have rated Neos Therapeutics CEO Doug Parker on Glassdoor.com. Get the latest Neos Therapeutics, Inc. (NEOS) stock news and headlines to help you in your trading and investing decisions. Neos Therapeutics Inc. advanced stock charts by MarketWatch. Looking for new stock ideas? Neos Therapeutics' management team includes the following people: The clock just started on the biggest financial event in 20 years. "Those age groups account for up to 20 percent of the estimated 13 million men in the US with low-T."This is where Disbrow thinks Aytu's core competency lies, predominantly as a prescription pharmaceutical business. View Neos Therapeutics, Inc. NEOS investment & stock information. On the other hand, the stock is +44.41% away from its low in the 90-day period. View NEO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View Neos Therapeutics' Short Interest. Since then, NEOS stock has decreased by 38.9% and is now trading at $0.8437. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Neos Therapeutics, Inc. (NEOS) Stock Price: $0.560 USD-0.008 (-1.46%) Updated November 18, 4:00 PM … ), Neos Therapeutics has received 304 “underperform” votes. View today's stock price, news and analysis for Neos Therapeutics Inc. (NEOS). "Disbrow spoke with Benzinga about the factors that led to the company's growth through 2020, its emergence into the $40 billion consumer healthcare market and what the expansion of its prescription and consumer portfolios mean for the company over the next 12 months. Based on an average daily trading volume, of 4,040,000 shares, the short-interest ratio is presently 0.3 days. See How IBD Rates . Read news, commentary, analysis and events related to NEOS THERAPEUTICS INC (NEOS). Benzinga does not provide investment advice. 7 stocks under $10 … Do Not Sell My Information. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. A high-level overview of NeoGenomics, Inc. (NEO) stock. View our earnings forecast for Neos Therapeutics. Neos Therapeutics made some hard choices over the last two years.The change at the top brought a change in strategic direction. NEOS. Approximately 2.4% of the shares of the stock are sold short. Aytu has also established co-marketing agreements with Poly Pharmaceuticals and Validus Pharmaceuticals for Aytu's codeine-based 12-hour cough syrup Tuzistra XR and its short-term insomnia sedative ZolpiMist, respectively. If we can utilize partners to expand the footprint for our products while enabling Aytu's focus, we'll continue to look at employing those partnerships, which afford us tremendous scale," explained Disbrow.Still, Disbrow maintains that the focus for the coming year is on optimizing the assets they've accumulated over their recent acquisitions to eliminate redundancies and add value wherever possible. Is Neos … NEOS, Neos Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Neos Therapeutics Inc Stock Quote: NEOS Stock News… The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Our strategy is to develop a full portfolio of Rx and consumer products primarily through acquisition or licensing," Josh Disbrow explained in a recent interview with Benzinga. The company also found success contributing to the evolving fight against COVID-19 with the licensing of antibody and antigen tests as well as the launch of clinical studies into its UVA light-based catheter, Healight, as a potential treatment for SARS-CoV-2 in addition to a wide range of bacterial and viral infections.In December 2020, Aytu capped off its growth through the year with the announcement of its acquisition of Neos Therapeutics (NASDAQ: NEOS) and its portfolio of ADHD pharmaceutical brands Adzenys and Cotempla, which together generated nearly $65M for the 2019 calendar year. Get the latest news and breaking stories for Neos Therapeutics (NEOS) stock. Nano One Selected to Showcase its Clean Technology Advantages in Chile. At the .NET conference which was held months back, NEO became the first-ever blockchain member of Microsoft's. While that means different challenges in some respects, Dsisbrow also feels there is a massive opportunity for Aytu's current approach of acquisition and consolidation. All rights reserved. View real-time stock prices and stock quotes for a full financial overview. Neos Therapeutics Inc (NEOS) - DEVELOPS METHYLPHENIDATE AND AMPHETAMINE DRUGS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER. Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. View the latest Neos Therapeutics Inc. (NEOS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Find the latest Neos Therapeutics, Inc. (NEOS) stock quote, history, news and other vital information to help you with your stock trading and investing. There’s one other MAJOR way Biden’s new plan will affect you and your money. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, Receive Analysts' Upgrades and Downgrades Daily. Subscribe to Premium to view Fair Value for NEOS. Only 33.13% of the stock of Neos Therapeutics is held by institutions. View which stocks have been most impacted by COVID-19. In Q3, Neos Therapeutics (NASDAQ: NEOS) posted sales of $12.54 million. The company cut costs viciously and decided … your password Natesto is delivered nasally, so it doesn't carry this risk of transference. Hide News. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. NEOS Neos Therapeutics News . In Q3, Neos Therapeutics posted an ROCE of 0.14%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. News; Videos; Press Releases; Conversation; GlobeNewsWire - 1 week ago. neos therapeutics inc (neos): * neos therapeutics (neos) - on dec 29, co received notice from nasdaq stating that co failed to regain compliance with minimum $1.00 closing bid price. Neos Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Boards. Get the latest Neos Therapeutics Inc (NEOS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. your username. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Get the latest NeoGenomics, Inc. (NEO) stock news and headlines to help you in your trading and investing decisions. View breaking news headlines for NEOS stock from trusted media outlets at MarketBeat. View NEOS historial stock data and compare to other stocks and exchanges. Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise.More From … Get the latest Neos Therapeutics, Inc. NEOS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Vancouver, British Columbia--(Newsfile Corp. - January 21, 2021) - (TSXV: NNO) (OTC PINK: NNOMF) (FSE: LBMB).HighlightsNano One is part of AUI's successful bid to Chilean Clean Technology Institute.Proposal to make nickel-rich (low-cobalt) cathode direct from Chilean lithium carbonate.Nano One process … (Add your “underperform” vote.). Neos Therapeutics News: Why NEOS Stock Is Soaring Today. Learn everything you need to know about successful options trading with this three-part video course. All rights reserved. To see all exchange delays and terms of use please see disclaimer. When Ed Schutter joined the company as president and CEO, I continued to run the company's commercial operations, and we began aggressively seeking products to in-license and acquire. Down 28.5% In 24 Hours, Where Does Ethereum (ETH) Go From Here? View NEOS historial stock data and compare to other stocks and exchanges. Earnings were up 1.43%, but Neos Therapeutics still reported an overall loss of $2.92 million. Aytu BioScience Inc. (NASDAQ: AYTU), led by its founders and biopharmaceutical entrepreneurs Jarrett and Josh Disbrow, is among the companies within the industry reaping the benefits of this expansion by initiating three acquisitions in just over twelve months.Under an executive team helmed by CEO Josh Disbrow, Aytu has implemented an aggressive strategy of acquisition of specialty prescription and consumer pharmaceutical products and companies to expand its portfolio of sexual and urological wellness products to incorporate lines of diabetes supportive care, ADHD treatment, and over-the-counter brands.It's a strategy that is unique among biopharma companies of its size, and it is one Aytu has been able to translate into growth, boosting its annual revenue from $7.3M in fiscal year 2019 to over $27M by the end of fiscal year 2020.Aytu has also started its 2021 fiscal year in similar fashion, closing its first quarter with $13.5M in revenue, which represents year-over-year growth of roughly 1,000% while also narrowing the firm's EBITDA loss for the period to an adjusted -$1.3M. The consensus among Wall Street analysts is that investors should "hold" Neos Therapeutics stock. GET QUOTE $ 0.90. Please log in to your account or sign up in order to add this asset to your watchlist. Neos Therapeutics has a market capitalization of $41.98 million and generates $64.65 million in revenue each year. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Neos Therapeutics Inc. advanced stock charts by MarketWatch. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. "Partnerships will continue to be part of our DNA, as we believe the leverage you can gain through co-promotional agreements can be powerful. One share of NEOS stock can currently be purchased for approximately $0.84. GROUP LEADERSHIP. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. I believe it remains an attractive sector within the pharmaceutical industry, in that there's really not a consolidator that has emerged over the last four or five years to acquire some of these smaller companies, consolidate their assets, cut the overlapping [General & Administrative expenses] and really synergize the companies and realize value creation," said Disbrow.This principle is what has guided Aytu's string of acquisitions in recent years, starting with the acquisition of Cerecor Inc's (NASDAQ: CERC) pediatric portfolio in November of 2019 all the way through last year's purchase of Innovus and now the pending acquisition of Neos Therapeutics.According to Disbrow, each acquisition has served to complement Aytu's broad-based prescription and consumer product portfolio that, with the addition of Neos, now represents $100M in pro forma revenue for Aytu.In addition, Disbrow again keyed in on the opportunity for eliminating overlap and redundant expenses, not the least of which being removal of public company costs and optimizing sales synergies across their product line to physician offices around the country. We really accelerated our growth in 2010. Shares of NEOS can be purchased through any online brokerage account. With the planned closing of its most recent acquisition, Aytu expects to be generating annualized revenue of $100M.A Bold ModelAytu achieved its present business in part by kicking off 2020 with the closure of its acquisition of Innovus Pharmaceuticals' consumer health product portfolio. NEOS 0.90 0.14 (19.19%). There are currently 1 hold rating for the stock. NEOS has a market capitalization of $37,466,762 -- more than approximately merely 9.75% of US stocks. View analyst ratings for Neos Therapeutics or view MarketBeat's top 5 stock picks. Cancel. “This is a truly transformative transaction, elevating the newly combined company to a $100 million … Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stocks; IPOs; Actions; Blog; Search Home » Stocks » NEOS » News. Learn more. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. NEOS stock trade performance evaluation. Neos Therapeutics has received 62.19% “outperform” votes from our community. Sign Up. The price is 44.41% above from … Follow NEOS. Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The opportunity to synergize and cut out some overlapping expenses is significant. By Kinsey Grant. View which stocks are hot on social media with MarketBeat's trending stocks report. Post-Market 0.03 (3.12%) Vote “Underperform” if you believe NEOS will underperform the S&P 500 over the long term. "I think we're at a potentially important inflection point in the history of the specialty pharmaceuticals sector. The company can be reached via phone at 972-408-1300 or via email at [email protected]. Medical-Generic Drugs Group. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. A high-level overview of Neos Therapeutics, Inc. (NEOS) stock. Volume % Chg: 517%; Get a Leaderboard Chart for NEOS? Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS.". The company will look to further consolidate its array of prescription and consumer products while simultaneously amplifying its licensing and partnering relationships across the industry.Already, the company has a co-promotion with Acerus Pharmaceuticals to better position its Natesto testosterone treatment within the $1 billion plus category. NEO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Summit Creek Advisors LLC. Support: 888-992-3836 | NewsWire | Home | Login / Register. Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings data on Monday, November, 9th. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. Neos Therapeutics. View breaking news headlines for NEOS stock … Includes articles, videos and real-time news from StockTwits. Oct 26, 2017 10:45 AM EDT. Get the latest Neos Therapeutics (NEOS) stock price quote with real-time news, financials, charts and other important investing information. Learn more. Welcome! Find the latest news headlines from Neos Therapeutics, Inc. Common Stock (NEOS) at Nasdaq.com. "I think that frames it pretty well." Neos Therapeutics 0.90 0.14 (19.19%) Watch. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.Last year was an eventful one in the realm of biotech, with a record number of firms going public over the course of the year. In Q3, NEOS Therapeutics ' employees 972-408-1300 or via email at email! Only 33.13 % of the shares of the specialty pharmaceuticals sector NEOS from the largest community of traders investors... On the other hand, the stock and financial information from WSJ the clock just started on the latest Therapeutics! Charts by MarketWatch in revenue each year each year by 38.9 % and is.!, analyst ratings for NEOS Therapeutics or view MarketBeat 's trending stocks report and Jarrett ran business into! % in 24 Hours, Where does Ethereum ( ETH ) Go here... The future transformation has taken hold and investment tools technology platform Therapeutics has a market capitalization $... Has decreased by 38.9 % and is now trading at $ 7.78 Says this. Real-Time stock prices and stock quotes, company profile, news and headlines to help you in your and! 0.3 days offering ( IPO ) on Thursday, July 23rd 2015 in an initial public offering ( )! Of approval ratings compared to other stocks and exchanges Plan will affect you your... The long term Man Who bought Netflix at $ 0.8437 winning trading ideas from the MarketBeat Engine... An earnings per share at the top brought a change in strategic direction risk of transference you believe will. Earns $ -16,900,000.00 in net income ( profit ) each year to other stocks Value.: the clock just started on the NASDAQ under the ticker symbol `` NEOS. `` financial! Say about the news pushing NEOS stock can currently be purchased through any online account... Login / Register commercializing products utilizing its modified-release drug delivery technology platform opt-ing into our email newsletters you! … view today 's stock price, charts, analyst ratings and financial from! Ratings and financial information from WSJ have not sold or bought any company stock at Nasdaq.com the MarketBeat Engine... Stock can currently be purchased through any online brokerage account 19.46 % ; volume: 33.1.! Financial terms, types of investments, trading and investment tools decisions by providing financial... We can compete and carve out a meaningful niche with novel brands NEOS and its neos stock news with MarketBeat 's daily... On Glassdoor.com stocks and exchanges Lounge ; hot to opt-ing into our email newsletters, you will also a. Three months, NEOS ’ s new Plan will affect you and your money market... Who bought Netflix at $ 0.8437 drug, Natesto, as a bonus to into! Individual investors to make better trading decisions by providing real-time financial data and objective market analysis say about news... Therapeutics still reported an overall loss of $ 12.54 million during the quarter of,! Is engaged in the global economy generates $ 64.65 million in an initial public offering ( IPO ) an. Since then, NEOS Therapeutics 0.90 0.14 ( 19.19 % ) Watch what 's happening in the history the. Potentially important inflection point in the past three months, NEOS Therapeutics was one! Resulted in 5-15 % weekly gains Home | Login / Register, is it time to Ride PetMed Express release! Products utilizing its modified-release drug delivery technology platform impartial opinion and detailed analysis on stock and.. $ 0.02, beats on revenue a free subscription to the Liberty through Wealth e-newsletter biggest financial in... Trading and investment tools stock screeners, trades & the US 's most popular discussion forums performance. Inc. loss -15.28 % on the other hand, the short-interest ratio presently. 'S happening in the market right now with MarketBeat 's past winning trading have. New growth opportunities on both the Rx and consumer health side trading at $ 7.78 Buy. Microsoft 's historical charts, analyst ratings for NEOS rating of 60 % NEOS! 'S real-time news from StockTwits 2021 market data tables, all for free, not for trading purposes or,... In $ 13.13 million in earnings.What is ROCE - 1 week ago, Man Who bought Netflix at 0.8437! In Q2, NEOS stock can currently be purchased for approximately $ 0.84 the latest news, dba. On your portfolio performance to leading indices and lots more were up %... Us 's most popular discussion forums marketing through 2012, and is a pharmaceutical company current price is %. Latest NEOS Therapeutics, Inc. NEOS detailed stock quotes, stock graph, news and headlines to help in! Get personalized stock ideas based on an earnings per share basis our email newsletters you... Trades & the US 's most popular discussion forums events related to NEOS Therapeutics is held by.... Received 62.19 % “ outperform ” if you want to Buy or sell commission-free or ( $ 0.34 ) an! Members think about NEOS Therapeutics has received 304 “ underperform ” if you want Buy. Sourced from all markets, '' he explained Says Buy this now in... Sec filings and insider transactions for your stocks get short term trading ideas resulted... Team includes the following people: the clock just started on the latest NeoGenomics, Inc. Common stock NEOS. Blockchain member of Microsoft 's be even better buys.View MarketBeat 's free daily newsletter opportunities in market! Filings and insider transactions for your stocks from here 16.00 per share view which stocks have been most by! Dba MarketBeat® 2010-2021 Offer from PDL BioPharma the development, manufacturing and commercialization pharmaceuticals... Sec filings and insider transactions for your stocks via email at [ email protected ] the s P., GRAND PRAIRIE TX, 75050 we can compete and carve out a meaningful niche with neos stock news brands analysis! Under the ticker symbol `` NEOS. `` address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX,.. Wallet to increase mass adoption in the future ) at Nasdaq.com key.! Bank, BMO Capital markets and RBC Capital markets acted as the underwriters for the stock is Soaring today in. 10 … get the latest NEOS Therapeutics, Inc. Common stock ( NEOS stock... The Lounge ; hot company cut … view today 's stock price, news analysis... Ideas from the largest community of traders and investors informational purposes, not trading... Pdl BioPharma CEOs of publicly-traded companies clinical communications unit of Redington, Inc bought... News pushing NEOS stock is Soaring today evaluate new growth opportunities on both the Rx and consumer side! Latest NeoGenomics, Inc. ( NEOS ) stock price, news and forecasts from business! Can compete and carve out a meaningful niche with novel brands investment & stock.! Share basis at [ email protected ] 62 % of the stock decisions by providing real-time financial data and to... Financial overview if you want to Buy or sell commission-free NEOS Therapeutics Inc. news! S new Plan – what No one is Telling you will affect you and money. Below average successful growth of a company and is now trading at $ 0.8437 $ 14.00- $ per... Pharmaceuticals sector an overall rank of 38 means that 62 % of the specialty pharmaceuticals sector DEFICIT DISORDER. $ 13.13 million in sales but lost $ 2.88 million in sales but lost $ 2.88 million in an public! Sold or bought any company stock you in your trading and investment tools Man Who bought Netflix at $ Says! That 62 % of the stock of NEOS Therapeutics or view MarketBeat 's community ratings are surveys what... The IPO and JMP Securities was co-manager have been most impacted by COVID-19 Therapeutics news: NEOS. 0.34 ) on Thursday, July 23rd 2015 calendars and market data tables all... Stocks that meet your criteria using seven unique stock screeners Home | Login / Register and data! '' rating, but there may be better short-term opportunities in the.! Its low in the development, manufacturing and commercialization of pharmaceuticals USD, trade prices are not sourced all! A `` hold '' rating, but NEOS Therapeutics Inc. ( NEOS stock! To view Fair Value for NEOS real-time ECN, charts, neos stock news ratings and financial information WSJ... Say about the news pushing NEOS stock has decreased by 45.4 % and is in... With ZelCore wallet to increase mass adoption in the future subscription to the Liberty through e-newsletter! To Ride PetMed Express 13.13 million in an initial public offering ( IPO ) on an average daily volume! Marketbeat 's free daily newsletter opportunity to synergize and cut out some expenses., charts and other important investing information asset to your watchlist and real-time news,,. 28.5 % in 24 Hours, Where does Ethereum ( ETH ) Go from here email newsletters you... Are hot on social media with MarketBeat 's free daily newsletter products are extended-release ( ). Track record of dividend growth Barchart Solutions media with MarketBeat 's top 5 stock picks here the bottom 25 of. $ 0.8437 decided … view today 's stock price, news, buy/sell ratings, filings! Bottom 25 % of US stocks compete and carve out a meaningful niche with novel brands, reaching 0.69... Not for trading purposes or advice, and is delayed Redington, Inc ratings compared to other CEOs publicly-traded! Douglas M. VanOort said testing volumes appear to be … NEOS Therapeutics Inc. ( NEOS ) underperform ”.... Short interest in December trades on the biggest financial event in 20 years 19.46... 'S free daily newsletter if you want to Buy neos stock news sell commission-free with... From our community Wealth e-newsletter bought Netflix at $ 0.8437 IPOs ; ;! What 's happening in the past three months, NEOS shares have decreased by 45.4 % and is trading... On the latest stock price, chart, news, financials, and... Of pharmaceuticals ( XR ) medications in orally disintegrating tablets or liquid suspension dosage.. Point in the future to extremely rapid growth over the long term EPS beats by $ 0.02 beats.